Acute coronary syndrome - rivaroxaban [ID532]: supporting information
01 – Pre-meeting briefing prepared by NICE
02 – Submission from the technology company – Bayer
03 – NICE request to the company for clarification on their submission
04 – Company’s clarification response
05 – Consultee submission – Pumping Marvellous Foundation
06 – Clinical expert statement – Cotton
07 – Clinical expert statement – Di Mario
08 – Patient expert personal perspective – Hartshorne Evans
09 – Patient expert personal perspective – Knowles Smith
10 – Evidence Review Group report prepared by School of Health Related Research, University of Sheffield
11 – Evidence Review Group report erratum
12 – Company factual accuracy check of Evidence Review Group report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
Acute coronary syndrome - rivaroxaban [ID532]: supporting information
22 October 2014 (14.41 Mb 39 sec) |
This page was last updated: 23 October 2014